Vaccines and Global Health: The Week in Review
18 February 2023 :: Issue 691
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
Dr Muhammad Ali Pate to become next CEO of Gavi, the Vaccine Alliance

- The Gavi Board has approved the appointment of Dr Muhammad Ali Pate as the Chief Executive Officer of the Vaccine Alliance following an extensive recruitment process.
- Dr Pate will assume the role as of 3 August 2023, replacing Dr Seth Berkley, who will step down after 12 years leading the Alliance.
- Dr Muhammad Ali Pate: “It will be my privilege to lead Gavi and continue to support countries to scale up critical routine immunisation programmes, reach more zero-dose children, expand access to new vaccines, transform primary health care systems, and help fight outbreaks and future pandemics.”

Geneva, 13 February 2023 – Gavi, the Vaccine Alliance announced today the appointment of Dr Muhammad Ali Pate as its new Chief Executive Officer. Dr Pate will be officially starting as CEO on 3 August 2023. A proven global health leader with experience at the national and international levels, Dr Pate will lead Gavi as it continues its work to support routine immunisation, outbreak response and COVID-19 vaccinations around the world.

Dr Muhammad Ali Pate, who was selected following a yearlong recruitment process personally overseen by the Chair of the Gavi Board, Professor José Manuel Barroso, will bring a wealth of experience to the role. A medical doctor trained in both internal medicine and infectious diseases, with an MBA from Duke University in the United States, Dr Pate served as Nigeria’s Minister of State for Health between 2011 and 2013. In this role, he led a flagship initiative to revive routine vaccinations and primary health care, chaired a presidential taskforce to eradicate polio and introduced new vaccines into the country.

While serving as Global Director for Health, Nutrition and Population of the World Bank and Director of the Global Financing Facility at the World Bank between 2019 and 2021, he led the Bank’s US$ 18 billion COVID-19 global health response and represented the Bank on various boards, including those of Gavi, the Global Fund, CEPI and UNAIDS. He is currently the Julio Frenk Professor of Public Health Leadership at Harvard Chan School of Public Health and has served on several health-focused boards and expert panels in the public, private and not-for-profit sectors during his career.

Commenting on the appointment, Professor Barroso said: “Dr Muhammad Ali Pate stood out in a field of world-class candidates. With his knowledge and experience of both national immunization programming and international emergency response and global finance, I am confident that Gavi will continue to build on its vision and mission, as well as navigate the many challenges and opportunities we will face.”

Dr Pate, whose appointment was confirmed today at an extraordinary meeting of the Gavi Board, said: “I’m deeply honoured to be joining Gavi as its incoming CEO. Gavi is one of the most impactful organisations in global health, a testament to the great work of the Alliance partners and Secretariat staff. It will be my privilege to lead it, building on the work of Dr Seth Berkley, and continue to support countries to scale up critical routine immunisation programmes, reach more
zero-dose children, expand access to new vaccines, transform primary health care systems, and help fight outbreaks and future pandemics.”

Commenting on Dr Pate’s appointment, Dr Berkley said: “Leading Gavi and helping the Alliance to continually surpass itself in terms of saving lives, protecting children and supporting countries during global health emergencies has been the greatest honour of my career. I am proud and humbled to have been part of what the Alliance has achieved, and I am confident in its future under Muhammad’s leadership: having worked with him during his time as Minister and at the World Bank, I know he understands intimately the landscape we work in and will be uncompromising in his drive for public health equity.”

Global Fund Provides US$867 Million in Additional Funding for Pandemic Preparedness and Response
14 February 2023

GENEVA – Since December 2022, the Global Fund has awarded US$547 million in additional funding to 40 countries through its COVID-19 Response Mechanism (C19RM) and has now initiated the process to award a further US$320 million, making a total of approximately US$867 million.

These grants are focused on supporting both the immediate COVID-19 response and broader pandemic preparedness, while strengthening the underlying health systems. This includes investments in disease surveillance, laboratory networks, community health worker networks and community-based organizations, medical oxygen and respiratory care systems, as well as the rollout of novel therapeutics to scale up test-and-treat programs in case of future COVID-19 surges. These investments reflect the deliberate rebalancing of C19RM from the immediate COVID-19 response towards strengthening key components of health systems to counter potential future variants and reinforce pandemic preparedness. The total awarded for C19RM since 2020 now amounts to almost US$5 billion.

The Global Fund’s C19RM follows a country-led, inclusive, and demand-driven approach to ensure funding goes where it is most needed...

Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - February 2023
14 February 2023  From Kate O’Brien, Director of the Department of Immunization, Vaccines and Biologicals at WHO

WHO, along with the IA2030 partners, has established 2023 as an intensified year of action on immunization. This call to action recognizes the importance for country immunization programmes to assess the impact of the pandemic on their programme performance and course correct where needed. This may involve the need to catch-up the accumulated zero-dose children through a variety of programmatic approaches; to recover the programmatic performance of DTP1 coverage to at least the levels of 2019 (pre-pandemic); and to strengthen the immunization
programme so that DTP1 coverage is better than the pre-pandemic levels and, on a trajectory, to achieve 2025 and 2030 zero-dose goals (i.e., half the number of 2019 zero-dose children by 2030). Harnessing the political leadership and prioritization of immunization resulting from the COVID pandemic experience is an opportunity to save millions of lives. The ambition to save 50 million lives in the IA2030 decade depends on this concerted action.

Together with our members states and key partners, WHO has been uncompromising in our commitment to get vaccination on global agendas, to enhance political dialogue and engagement, and to leverage the resources needed to implement. The COVID pandemic put the spot-light on the value of vaccines, and demonstrated what could be achieved with concerted, aligned effort. This year we are not only continuing the work to protect the high priority populations with COVID vaccine but are also intensifying our efforts on routine immunization, aiming to claw back what was lost on programmatic performance and push to reduce the number of zero-dose children.

With this as our overarching priority so as to address the worst continued decline in routine immunization coverage in 30 years, together with the IVB Leadership Team, I recently visited our Africa Regional Office and three priority country offices, the Democratic Republic of Congo (DRC) and Mozambique.

The visits were supporting the Essential Immunization Recovery Plan in the African Region that has been developed in partnership with UNICEF and Ministries of Health to ensure that countries get back on track to reach the Immunization Agenda 2030 (IA2030) goals...

...Another area of our intensified focus is on building demand for immunization. This is key to ensuring the use and impact of any new vaccines. With 80% of vaccines in development focused on adults, ensuring uptake among this group is vital. With that in mind we are intensifying our work to advance new TB and RSV vaccines, which are at different stages in the development value chain but are both diseases which significant burden for which vaccines would have a significant impact. The WHO Director General announced on 16 January 2023 at the World Economic Forum that he would be initiating a TB Vaccine Acceleration Council in order to increase momentum for the development of a vaccine to combat the world’s most deadly infectious disease. This will be an important means to accelerate the development of TB vaccines that are much more impactful on TB disease and transmission than the tools in hand presently. WHO looks forward to expanding partnerships and working with political leaders, advocates, academics, research institutions, communities and many other stakeholders to advance this critical area of innovation and development.

Finally, as data is key to all that we do, please join us in celebrating the second anniversary of the Electronic Joint Reporting Form on Immunization (eJRF). The eJRF is an online immunization data collection portal open to all Member States, Reporting Entities, and Associate Members. Please join me in appreciating and celebrating the profound impact of the eJRF in informing and guiding action on vaccine impact.

:::::
:::::

“Pandemic Treaty”

Intergovernmental Negotiating Body 27 February - 3 March 2023
Pharma recommends five priorities for future pandemic preparedness and response

IFPMA Press release  13 Feb 2023

As the international community discusses a future pandemic architecture fit for purpose to prepare and respond to public health emergencies, the innovative pharmaceutical industry outlines five priorities that the COVID-19 pandemic has shown to be fundamental. These priorities are critical to develop and deploy countermeasures even faster and more effectively and achieve greater health equity from the outset of future pandemics.

A new architecture needs to maintain what has proven to be effective in addressing this pandemic: a thriving innovation environment made possible thanks to unimpeded and swift access to emerging pathogens and an R&D ecosystem supported by a tried and tested intellectual property framework. However, the inequities in access to COVID-19 vaccines, treatments, and diagnostics despite major global efforts must be overcome. As the global architecture for pandemic preparedness and response is discussed, the innovative pharmaceutical industry shares practical solutions and recommends focusing on:

- **Sustaining a thriving innovation ecosystem** that can be counted on to deliver rapid research and development of new pandemic countermeasures, as proposed in the 100 Day Mission, and guaranteeing fast, certain, and unencumbered access to pathogens and their genetic information. Intellectual property incentives are critical to a thriving innovation ecosystem on which global health security can depend. They provide the necessary framework that makes at risk investments possible in advance of the next pandemic, and they facilitate voluntary partnerships, business-to-business agreements, technology transfer, and other forms of collaboration.

- **Building equitable access early on into pandemic responses, shaping a new social contract**, as outlined in the industry proposal, to reserve an allocation of real-time production of vaccines and treatments for future pandemics for priority populations in lower income countries and take measures to make them available and affordable.

- **Fostering sustainable manufacturing globally that can scale-up for high volume supply in future pandemics**. The right enabling environment to attract sustainable investments and predictable demand will be critical to maintain existing capacity and introduce new capacity in other regions. Robust intellectual property protection is a requirement for fast-tracking partnerships, including for voluntary licensing and/or early voluntary technology transfers that result in a lasting and economically viable manufacturing base that produces safe, effective, and quality products.

- **Supporting a trading environment that contributes to global health security with open borders and the removal of trade restrictions** to counter vaccine nationalism and enable the free movement of vaccines, treatments, and their raw materials and supplies, as well as the movement of people needed to support their manufacture by sharing technical know-how.

- **Supporting ongoing efforts to ensure greater country readiness to anticipate and respond to future pandemics** through investing in key health system capabilities, including life-
course immunization programs. Improved and expanded pathogen sharing and disease surveillance are needed, alongside robust pandemic plans to deliver pandemic vaccines, treatments, and diagnostics and care to populations in all countries, while maintaining access to routine and essential health services. Progress should be built on, and complement, progress towards Universal Health Coverage, which is an essential foundation for effective pandemic prevention, preparedness, and response...

Statement on avian influenza and mammals
World Organisation for Animal Health (OIE)
Published on 13 February 2023
The current avian influenza situation has been raising concerns within the international community. Since October 2021, an unprecedented number of outbreaks has been reported in several regions of the world, reaching new geographical areas and causing devastating impacts on animal health and welfare. The disease puts at risk global food security and the livelihoods of those who depend on poultry farming. It has also led to an alarming rate of wild bird die-offs and has affected other wildlife including sea and land mammals.

While it primarily affects poultry and wild birds, avian influenza can occasionally be transmitted to mammals, including humans. A rising number of H5N1 avian influenza cases has been reported in several mammalian animals both terrestrial and aquatic, causing morbidity and mortality. This sparks growing concern about the threat for the health of domestic and wild animals, biodiversity, and potentially for public health.

The current situation highlights the risk that H5N1 avian influenza may become better adapted to mammals, and spill over to humans and other animals. In addition, some mammals, such as mink, may act as mixing vessels for different influenza viruses, leading to the emergence of new strains and subtypes that could be more harmful to animals and/or humans. Recently reported infections in farmed mink are a concern because infections of large numbers of mammals kept in close proximity of each other exacerbate this risk. Several studies are currently on-going to further explore the virulence and transmissibility (including between mammals) of these viruses.

In collaboration with its network of experts, the World Organisation for Animal Health (WOAH) is closely monitoring the situation to assess the risks to animals and humans.

WOAH calls on its Members to:
- Maintain enhanced disease SURVEILLANCE in domestic and wild birds.
- PREVENT the spread of the disease by implementing strict biosecurity measures in poultry holdings. In particular, step up the biosecurity around mink farms to avoid the introduction of the virus.
- CONTROL movements of susceptible domestic animals and their products to avoid disease spread.
- PROTECT humans in close contact with, or handling poultry or sick domestic or wild animals. Exposed humans should always take precautionary measures, including wearing personal protective equipment (PPE), particularly when investigating die-offs or outbreaks.
- **MONITOR susceptible domestic and wild animals.** Investigate any unusual increase of mortality events in wild animals (die-offs).
- **REPORT cases of avian influenza in all species** to WOAH through WAHIS and in accordance with international standards. Timely and transparent reporting is key to maintain a good knowledge of the disease situation and to prevent any type of misinformation or disinformation.
- **SHARE genetic sequences** of avian influenza viruses in publicly available databases.

WOAH is fully committed to supporting its Members mitigate risks against the impact of avian influenza and will continue to engage with its networks of experts as well as public and private partners, notably through the One Health Quadripartite Alliance and the Global Framework for transboundary animal diseases (GF-TADs) to provide technical updates as more information becomes available.

---

**PHEIC**

**Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*


**Weekly Epidemiological and Operational updates**

*Last update: 17 Feb 2023*

- **Confirmed cases:** 756 581 850
- **Confirmed deaths:** 6 844 267
- **Vaccine doses administered:** 13 195 832 385

**Weekly epidemiological update on COVID-19 - 15 February 2023**

**Overview**

Globally, over 6.7 million new cases and over 64 000 deaths were reported in the last 28 days (16 January to 12 February 2023), a decrease of 92% and 47%, respectively, compared to the previous 28 days. As of 12 February 2023, over 755 million confirmed cases and over 6.8 million deaths have been reported globally.

---

*Figure 1. COVID-19 cases reported by WHO Region, and global deaths by 28-day intervals, as of 12 February 2023*
UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 18 Feb 2023
An overview of information collected from publicly announced bilateral and multilateral supply agreements

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 18 Feb 2023]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

COVID-19 Global Targets and Progress Tracker – IMF
This tracker was last updated on May 5 2022. We have archived the information and will no longer provide updates.

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.
Our World in Data
Coronavirus (COVID-19) Vaccinations [Accessed 18 Feb 2023]
:: 69.5% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.29 billion doses have been administered globally, and 604,771 are now administered each day.
:: 26.9% of people in low-income countries have received at least one dose.

Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Overview of donations by top 10 donating countries
Bar chart is ordered by total number of doses pledged.
Donut charts are ordered by proportion of pledged donations shipped.
Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
Feb 18, 2023 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 125M total confirmed cases; 2.3M total confirmed deaths
Global vaccines administered: 13.3B
Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 390M
Other Delivered (Number of Doses): 430M
Total Delivered (Number of Doses): 830M
Total Administered (Number of Doses): 580M

U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

HHS
News
No new digest content identified.
FDA
Press Announcements
No new digest content identified.

FDA VRBPAC
Vaccines and Related Biological Products Advisory Committee February 28 - March 1, 2023
Meeting Announcement

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency [EMA]
News & Press Releases
No new digest content identified.

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
News/Updates/Reports [Selected]
Weekly COVID-19 country overview
Epidemiological update - 17 Feb 2023

Outbreak of Shigella sonnei in the EU/EEA and the United Kingdom among travellers returning from Cabo Verde
News - 17 Feb 2023

Joint ECDC-WHO/Europe mpox (monkeypox) surveillance bulletin
Epidemiological update - 15 Feb 2023

Mpx (formerly named monkeypox) situation update, as of 14 February 2023
Epidemiological update - 15 Feb 2023

Pre-exposure prophylaxis for HIV prevention – priorities for action in the European region
Press release - 14 Feb 2023

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – “the first registered COVID-19 vaccine”
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.
China

China CDC *Weekly Reports: Current Volume (5)*
2023-02-17 / No. 7 COVID-19 ISSUE (35)
View PDF of this issue

**Vital Surveillances: Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023**

**Abstract**

**Introduction**

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has generated 2,431 variants over the course of its global transmission over the past 3 years. To better evaluate the genomic variation of SARS-CoV-2 before and after the optimization of coronavirus disease 2019 (COVID-19) prevention and control strategies, we analyzed the genetic evolution branch composition and genomic variation of SARS-CoV-2 in both domestic and imported cases in China (the data from Hong Kong and Macau Special Administrative Regions and Taiwan, China were not included) from September 26, 2022 to January 29, 2023.

**Methods**

Analysis of the number of genome sequences, sampling time, dynamic changes of evolutionary branches, origin, and clinical typing of SARS-CoV-2 variants submitted by 31 provincial-level administrative divisions (PLADs) and Xinjiang Production and Construction Corp (XPCC) was conducted to assess the accuracy and timeliness of SARS-CoV-2 variant surveillance.

**Results**

From September 26, 2022 to January 29, 2023, 20,013 valid genome sequences of domestic cases were reported in China, with 72 evolutionary branches. Additionally, 1,978 valid genome sequences of imported cases were reported, with 169 evolutionary branches. The prevalence of the Omicron variants of SARS-CoV-2 in both domestic and imported cases was consistent with that of international epidemic variants.

**Conclusions**

This study provides an overview of the prevalence of Omicron variants of SARS-CoV-2 in China. After optimizing COVID-19 prevention and control strategies, no novel Omicron variants of SARS-CoV-2 with altered biological characteristics or public health significance have been identified since December 1, 2022.


**Abstract**

**Introduction**

On December 7, 2022, China implemented the “Ten New Measures” to optimize its prevention and control measures for coronavirus disease 2019 (COVID-19). To provide the
latest data after the optimization, we evaluated trends of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection among the community population in China.

Methods
We utilized data from the National Sentinel Community-Based Surveillance (NSCS) system in China to
assess trends of SARS-CoV-2 infection. NSCS is a national community-based surveillance cohort with
0.42 million participants from all 31 provincial-level administrative divisions (PLADs) and Xinjiang
Production and Construction Corp (XPCC). Participants were tested for infection twice a week (a total of
eight rounds) from December 16, 2022 to January 12, 2023. SARS-CoV-2 infection was defined as
testing positive for SARS-CoV-2 nucleic acid or antigen. We calculated the daily average of newly
positive rates of SARS-CoV-2 infection.

Results
In this national cohort, the daily average newly positive rate of SARS-CoV-2 infection
decreased from 4.13% in Round 1 (December 16–19, 2022) to 0.69% in Round 8 (January
10–12, 2023). The epidemic peak occurred in Round 2 (December 20–22, 2022). Similar
trends were observed in urban areas (decreasing from 4.65% to 0.73%), rural areas (decreasing from
2.83% to 0.57%), the eastern region (decreasing from 4.18% to 0.67%), the central region
(decreasing from 5.43% to 0.61%), and the western region (decreasing from 3.01% to 0.77%).

Conclusions
NSCS data showed that the peak of SARS-CoV-2 infection in China had passed. SARS-CoV-2 infection in community populations in China is currently at a low epidemic level.

Vital Surveillances: SARS-CoV-2 Surveillance Through China Influenza Surveillance
Information System — China, December 1, 2022 to February 12, 2023

Preplanned Studies: Epidemic Features of COVID-19 and Potential Impact of Hospital
Strain During the Omicron Wave — Australia, 2022

-----

PHEIC
Mpox
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

Multi-country outbreak of mpox, External situation report #16 - 16 February 2023

-----

Fourth meeting of the International Health Regulations (2005) (IHR) Emergency
Committee on the Multi-Country Outbreak of monkeypox (mpox)
15 February 2023 — The WHO Director-General transmits the report of the fourth meeting of the
International Health Regulations (2005) (IHR) Emergency Committee regarding the multi-country
outbreak of monkeypox (mpox), held on Thursday, 9 February 2023 from 12:00 to 17:00 CET.
Following a series of consultations with global experts, WHO recommends a new preferred term “mpox” as a synonym for monkeypox. Both names will be used simultaneously for one year while the term “monkeypox” is phased out. This report uses the term “mpox” (for more information see [here](#)).

The Emergency Committee acknowledged the progress made in the global response to the multi-country outbreak of mpox and the further decline in the number of reported cases since the last meeting. The Committee observed that a few countries continued to see a sustained incidence of illness; the Committee is also of the view that underreported detection and under-reporting of confirmed cases of illness in other regions is likely. **Therefore, the Committee considered various options to sustain attention and resources to control the outbreak and advised maintaining the Public Health Emergency of International Concern (PHEIC), while beginning to consider plans to integrate mpox prevention, preparedness and response within national surveillance and control programmes, including for HIV and other sexually transmissible infections.**

**The WHO Director-General expresses his gratitude to the Chair, Members, and Advisers for their advice and concurs with this advice that the event continues to constitute a PHEIC for the reasons detailed in the proceedings of the meeting below and issues revised Temporary Recommendations in relation to this PHEIC, which are presented at the end of this document...**

::
::
::

**PHEIC**

**Polio**

**Polio this week as of 15 February 2023 - GPEI**

*Headlines*

:: Building Momentum for Routine Immunization Recovery in Africa: On 19 February, a high-level side-event at the African Union Heads of State and Government Summit in Addis Ababa, Ethiopia, will be held, co-hosted by the Republic of Sierra Leone. The event will bring together regional and global dignitaries and experts, to renew focus on immunization across the continent.

:: For a summary of polio-related activities in Pakistan for the last two weeks, take a look at the latest National Emergency Operations Centre (NEOC) Newsletter

*Summary of new polioviruses this week:*
- Afghanistan: two WPV1 positive environmental samples
- Benin: one cVDPV2 positive environmental sample
- Chad: seven cVDPV2 cases
- DRC: six cVDPV2 cases
- Indonesia: one cVDPV2 case
- Nigeria: four cVDPV2 cases
- Yemen: 10 cVDPV2 positive environmental samples

::
::
::
UN OCHA – Current Emergencies
Current Corporate Emergencies

**Afghanistan**
No new digest content identified.

**Ethiopia**
No new digest content identified.

**Somalia**
No new digest content identified.

**Ukraine**
Last Updated: 10 Feb 2023

WHO & Regional Offices [to 18 Feb 2023]
https://www.who.int/news
Selected News/Announcements/Statements
15 February 2023  Statement
Fourth meeting of the International Health Regulations (2005) (IHR) Emergency Committee on the Multi-Country Outbreak of monkeypox (mpox)

14 February 2023  Departmental news
**Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - February 2023**

13 February 2023  Departmental news
**New certification recognizes WHO commitment to high-quality humanitarian learning**

WHO Regional Offices
Selected Press Releases, Announcements

**WHO African Region**
:: **New cholera cases in Africa surging fast, reach a third of 2022 total in a month**
  09 February 2023  Brazzaville – Africa is witnessing an exponential rise in cholera cases amid a global surge. Cases recorded on the continent in the first month of 2023 alone have already risen by more than 30% of the total caseload reached in the whole of 2022.
  An estimated 26 000 cases and 660 deaths have been reported as of 29 January 2023 in 10 African countries facing outbreaks since the beginning of the year. In 2022 nearly 80 000 cases and 1863 deaths were recorded from 15 affected countries. If the current fast-rising trend continues, it could surpass the number of cases recorded in 2021, the worst year for cholera in Africa in nearly a decade. Average case fatality ratio is currently almost at 3%, above the 2.3% reached in 2022, and far exceeding the acceptable level of below 1%.
The bulk of the new cases and deaths have been recorded in Malawi, which is facing its worst cholera outbreak in two decades...

:: [Over 33 million children vaccinated against wild poliovirus in southern Africa](https://www.who.int/news-room/events-2023/17-february-2023-over-33-million-children-vaccinated-against-wild-poliovirus-in-southern-africa) 17 February 2023  
Brazzaville – A year since Malawi confirmed its first case of wild poliovirus type 1 in 30 years, more than 33 million children across five southern African countries have been vaccinated against the virus, with over 80 million vaccine doses administered over the past year...


**WHO Region of the Americas** PAHO

:: [PAHO provides guidance to countries in response to increased chikungunya cases](https://www.who.int/news-room/events-2023/15-february-2023-paho-provides-guidance-to-countries-in-response-to-increased-chikungunya-cases) 15 February 2023  
Washington, DC, February 15, 2023 (PAHO) - The Pan American Health Organization (PAHO) has called on countries of the Americas to strengthen measures to diagnose and manage chikungunya due to an increase in cases in some areas, higher numbers of susceptible persons and the start of peak transmission season in the Southern Cone. Chikungunya fever...

:: [PAHO launches campaign to raise awareness of childhood cancer in Latin America and the Caribbean](https://www.who.int/news-room/events-2023/14-february-2023-paho-launches-campaign-to-raise-awareness-of-childhood-cancer-in-latin-america-and-the-caribbean) 14 February 2023  
While treatment prognosis is high in children, survival rates vary between 20-80% in the region due to delays in diagnosis, lack of specialized care and limited access to cancer medicines. Washington D.C. 14 February 2023 (PAHO) – A new campaign launched by the Pan American Health Organization (PAHO), St. Jude Children’s Research Hospital and...

**WHO South-East Asia Region** SEARO

No new digest content identified.

**WHO European Region** EURO

:: 17 February 2023  
News release 

**WHO Western Pacific Region**

No new digest content identified.

:::...

**Disease Outbreak News (DONs)**

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

17 February 2023  |  [Nipah virus infection - Bangladesh](https://www.who.int/news-room/events-2023/17-february-2023-nipah-virus-infection-bangladesh)

:::...

**New WHO Publications**

[https://www.who.int/publications/i](https://www.who.int/publications/i) 
Selected Titles

17 February 2023
WHO Global Clinical Data Platform for the clinical characterization of Ebola: Statistical analysis plan...

16 February 2023

A clinical case definition for post COVID-19 condition in children and adolescents by expert

16 February 2023

Communicating with caregivers about the Human Papillomavirus vaccination: facilitator’s guide

16 February 2023

Communicating with caregivers about the Human Papillomavirus vaccination: a tool to build

13 February 2023

Adaptation and implementation of WHO’s multisectoral accountability framework to end TB...

CDC/ACIP [U.S.] [to 18 Feb 2023]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases
No new digest content identified.

CDC Funding Announcements

AWARD OF A SINGLE-SOURCE COOPERATIVE AGREEMENT TO FUND AFRICA CENTRES FOR DISEASE CONTROL AND PREVENTION
Filed on: 02/17/2023 at 8:45 am
FR Document: 2023-03530

SUMMARY:
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $3,000,000 with an expected total funding of approximately $15,000,000 over a 5-year period, to Africa Centres for Disease Control and Prevention. This award will strengthen and reinforce Africa’s public health systems to prevent, detect, and respond quickly and effectively to public health threats, using evidence-based programs and interventions.

AWARD OF A SINGLE-SOURCE COOPERATIVE AGREEMENT TO FUND THE INTERNATIONAL FEDERATION OF RED CROSS AND RED CRESCENT SOCIETIES
Filed on: 02/17/2023 at 8:45 am
FR Document: 2023-03522

SUMMARY:
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $6,000,000 for Year 1 funding to the International Federation of Red Cross and Red Crescent Societies. The award will utilize IFRC's unique expertise, skills and access to countries and subnational consequential geographies that are inaccessible to CDC personnel, to continue polio eradication activities as well as to deliver measles and other life-saving vaccine preventable disease (VPD) interventions in priority countries. Funding amounts for years 2-5 will be set at continuation.

ACIP Meetings
Next ACIP Meeting: February 22-23, 2023
Final Agenda
Webcast Link

MMWR Weekly
February 17, 2023 / No. 7
PDF of this issue
- Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023
- COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months–4 Years — United States, June 20–December 31, 2022
- COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults — United States, November–December 2022

Coronavirus Disease 2019 (COVID-19)- CDC
Announcements/reports/data summaries.
2/16/23
COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults — United States, November–December 2022

2/16/23
COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months–4 Years — United States, June 20–December 31, 2022

Africa CDC  [to 18 Feb 2023]
http://www.africacdc.org/
News
Call for Applications

Call for Applications for the African Union (AU) COVID-19 Vaccination Bingwa initiative – Southern and Western Africa Regions

15 February 2023

... Africa CDC is therefore announcing a call for applications for young Africans from the Southern and Western Africa regions who are motivated and willing to contribute to the acceleration of the COVID-19 vaccination uptake in their countries, to apply for the African Union COVID-19 Vaccination BINGWA initiative. The selected BINGWAs (champions) are expected to perform the following duties for a period of up to 12 months:

1. Develop a community engagement plan to mobilize their respective communities including friends and families to get vaccinated fully against COVID-19
2. Support capacity building efforts to onboard social actors within the community to help mobilize for the COVID-19 vaccinations
3. Organize innovative youth-focused events to mobilize young people and the broader community to take up the COVID-19 vaccines e.g. Campaigns, community mobilization, peer-to-peer advocacy, etc.
4. Serve as AU/Africa CDC focal points for youth vaccination in their respective countries.
5. Participate in the capacity building training organized by Africa CDC in preparation of their deployment to respective countries/communities.
6. Document progress recorded in mobilizing their respective communities and the improvement in vaccination rates in their community...

Statement

Statement from Africa CDC on the Pandemic Fund[1]

15 February 2023

Addis Ababa, Ethiopia – Africa CDC welcomes the call by the Pandemic Fund on 3rd February 2023, seeking Expressions of Interest (EOI) for potential projects to be funded under its first Call for Proposals. Africa CDC further encourages African Union (AU) Member States to actively participate in the Pandemic Fund activities and submit their EOIs by the set date of 24 February 2023. Africa CDC has made itself available to support AU Member States and other regional entities as they develop and submit their EOIs and proposals.

Africa CDC is an observer at the Board of the Pandemic Fund, and we have emphasised the need for inclusive representation in the governance structures, and technical teams and the Secretariat to inform the important work of the Pandemic Fund. We are pleased to note that regional and gender balance at these three levels continues to improve as the Fund evolves...

Press Releases

Press Release on Marburg Virus Disease in Equatorial Guinea

14 February 2023

Addis Ababa, Ethiopia – On 13 February 2023, the Ministry of Health and Social Welfare (MoH) of Equatorial Guinea reported a confirmed Marburg virus disease (MVD) outbreak in the Kie Ntem province in the North Western part of the country. One confirmed case, nine deaths and 16 suspected cases have been reported from two communities in this province. This is the first MVD outbreak that has ever been declared in Equatorial Guinea. The source of this outbreak is still unclear and genome sequencing results are still pending...

With partners’ support, the Ministry of Health and Social welfare has deployed rapid response teams to support further investigations. In addition, active case search, contact tracing and case management are ongoing in affected communities...
China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 18 Feb 2023]
http://en.nhc.gov.cn/
News
No new digest content identified.
[Editor’s Note: The most recent post on this site is 24 Dec 2022, representing the last daily report on confirmed COVID-19 infections.]

National Medical Products Administration – PRC [to 18 Feb 2023]
http://english.nmpa.gov.cn/
No new digest content identified.
[Editor’s Note: The most recent COVID post on this site is 27 Dec 2022, and the last daily report on confirmed COVID-19 cases is dated 21 Dec 2022. These daily reports had been regular over the last year+]

Organization Announcements

Paul G. Allen Frontiers Group [to 18 Feb 2023]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation [to 18 Feb 2023]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 18 Feb 2023]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
News: Articles and Publications
Calibr and Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Candidate Tuberculosis Treatment Compound
Calibr, a division of Scripps Research dedicated to the “bench to bedside” development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment.

CARB-X  [to 18 Feb 2023]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 18 Feb 2023]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – February 2023 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations  [to 18 Feb 2023]
http://cepi.net/
Latest News
CEPI and partners collaborate to advance key tools for Sudan ebolavirus vaccine research
15 February 2023, OSLO, Norway: The Coalition for Epidemic Preparedness Innovations (CEPI) is supporting the development of an international antibody standard against Sudan ebolavirus (SUDV) – a critical tool which will be used to assess and compare the performance of vaccines against the deadly disease responsible for a recent outbreak of Ebola disease in Uganda which was declared over on 11 January 2023.
CEPI is providing funding of US$562,000 to established implementing partners Integrum Scientific and the Department of Arbovirology, Emerging and Re-emerging Infectious Diseases at the Uganda Virus Research Institute (UVRI) to collect and test convalescent sera from people previously infected with SUDV. These samples will enable the development of, and global access to, an international antibody standard which would standardize assessment of vaccine candidates against the virus. This could contribute to the eventual licensure of vaccines against the disease, for which there are currently no authorized vaccines or therapeutics...

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES  [to 18 Feb 2023]
https://cioms.ch/
News; Publications; Events
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.]  [to 18 Feb 2023]
https://www.darpa.mil/news
News
DARPA RPM Aims to Speed-Up Production of On-Demand Protein-Based Therapeutics

Department of Defense (DoD) access to critical protein-based therapeutics is limited by the slow pace and substantial costs associated with current protein production methods. The goal of the DARPA Reimaging Protein Manufacturing (RPM) program is to develop tools for distributed, on-demand manufacturing of protein-based drugs, such as antibodies or vaccines, or the proteins required to make them. DARPA has selected performer teams that aim to demonstrate immediate production -- initiated within 24 hours -- of protein products with yields in excess of 500 units per week with correct protein modifications.

Duke Global Health Innovation Center [to 18 Feb 2023]
https://dukeghic.org/

Our Blog
Fatal Lack of Oxygen During Pandemic Peaks Spurs Action to End Enduring Shortages
The Global Accountability Platform (COVID GAP) blog series.

February 10, 2023 By Nellie Bristol Access to medical oxygen literally has been a matter of life and death during COVID-19 peaks and shortages have had devastating effects in many countries around the

EDCTP [to 18 Feb 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center [to 18 Feb 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 18 Feb 2023]
http://www.euvaccine.eu/
Latest News, Events
News, Events
No new digest content identified.

Evidence Aid [to 18 Feb 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Resources [Selected]
No new digest content identified.

**Fondation Merieux** [to 18 Feb 2023]
http://www.fondation-merieux.org/
News, Events
Mérieux Foundation co-organized event
**Epidemiology in complex emergencies for effective surveillance and response**
March 20 - 24, 2023 - Les Pensières Center for Global Health, Veyrier-du-Lac (France)
The objective of the Advanced Epidemiology Course is to strengthen the knowledge and skills of French-speaking epidemiologists in responding to outbreaks related to communicable diseases or natural disasters affecting a country, in the context of a complex emergency.

**Gavi** [to 18 Feb 2023]
https://www.gavi.org/
News Releases
13 February 2023
**Dr Muhammad Ali Pate to become next CEO of Gavi, the Vaccine Alliance**

**GHIT Fund** [to 18 Feb 2023]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified.

**Global Fund** [to 18 Feb 2023]
News & Stories
14 February 2023
**Global Fund Provides US$867 Million in Additional Funding for Pandemic Preparedness and Response**
Since December 2022, the Global Fund has awarded US$547 million in additional funding to 40 countries through its COVID-19 Response Mechanism (C19RM) and has now initiated the process to award a further US$320 million, making a total of approximately...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 18 Feb 2023]
https://www.glopid-r.org/news/
News
No new digest content identified.

**Hilleman Laboratories** [to 18 Feb 2023]
http://www.hilleman-labs.org/
News & Insights
Breakthrough Discoveries in Human Immunology – Michelson Philanthropies and AAAS/Science Award Transformative Research
- Michelson Philanthropies and AAAS/Science announce the recipients of the 2023 Michelson Philanthropies & Science Prize for Immunology.
- The grand prize is awarded to Dr. Aleksandar Obradovic, Dr. Roser Vento-Tormo and Dr. Joshua Tan receive finalist awards.
- The Michelson Philanthropies & Science Prize for Immunology is awarded annually to early-career investigators who conduct transformative research with lasting impact on vaccine and immunotherapeutic discovery.

General misinformation, disinformation and hate speech - Questions and answers
How is misinformation, disinformation and hate speech (also known as MDH) harmful for populations affected by conflict and humanitarian operations? Misinformation and disinformation can increase people's exposure to risk and vulnerabilities.
17-02-2023 | Article
IFRC  [to 18 Feb 2023]
Press Releases [Selected]
Press release 16/02/2023
Syria and Türkiye: IFRC increases emergency funding ask to CHF 650 million, as humanitarian needs rise

Institut Pasteur  [to 18 Feb 2023]
Press Documents
No new digest content identified.

ISC / International Science Council  [to 18 Feb 2023]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Latest Updates
No new digest content identified.

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
No new digest content identified.

IVAC  [to 18 Feb 2023]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
IVAC Economics & Finance Team Highlights Immunization Financing Gap
February 2023
IVI  [to 18 Feb 2023]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security  [to 18 Feb 2023]
https://www.centerforhealthsecurity.org/news/center-news/
Center News  [Selected]
No new digest content identified.

MSF/Médecins Sans Frontières  [to 18 Feb 2023]
http://www.msf.org/
Latest [Selected Announcements]
Natural disasters
Hospitals overwhelmed after earthquakes: "The rooms were covered in blood"
Voices from the Field 17 Feb 2023

Natural disasters
Vital needs grow in northwest Syria after the earthquakes
Project Update 15 Feb 2023

National Academy of Medicine - USA  [to 18 Feb 2023]
https://nam.edu/programs/
News [Selected]
No new digest content identified.
On Supporting Science in Ukraine One Year After the Invasion
February 14, 2023
As the one-year anniversary of the war in Ukraine approaches NAS President Marcia McNutt and the presidents of the national science academies of Poland and Ukraine urge the scientific community around the world to continue helping scientists from and in Ukraine and to plan for the post-war recovery of science there.

Agenda for Third International Summit on Human Genome Editing March 6-8
February 14, 2023
The final agenda is now available for the Third International Summit on Human Genome Editing to be held March 6-8 in London and virtually. The National Academy of Sciences and National Academy of Medicine are among the international partners hosting the summit.

NIH software assembles complete genome sequences on-demand
February 16, 2023 — Software opens the door for a greater number of complete genome sequences.

NIH RECOVER research identifies potential long COVID disparities
February 16, 2023 — NIH-supported studies show variations in symptoms and diagnostic experiences among different racial and ethnic groups.

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19
February 15, 2023 — Trial protocol may be adapted to evaluate additional therapeutics.

NIH scientists develop mouse model to study mpox virulence
February 14, 2023 — A 2022 outbreak of mpox infected more than 80,000 people in more than 100 locations worldwide.

Lingering symptoms common after COVID hospitalization
February 14, 2023 — Many adults experience problems like coughing, chest pain, and fatigue six months after their stay.
Press Releases
No new digest content identified.

Rockefeller Foundation [to 18 Feb 2023]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
Feb 15 2023 Press Releases
The Rockefeller Foundation Extends Project ACT to Continue Providing Free At-home Covid-19 Tests to At-risk Communities in Six States
Agreement Brokered by The Rockefeller Foundation’s Public Charity RF Catalytic Capital Keeps Per-test Price Under $7, Commitments from States Now Total $33.2 Million

Feb 13 2023 Press Releases
Advanced Surveillance Project Using Artificial Intelligence Aims to Anticipate Alerts of Infectious Disease Outbreaks
RIO DE JANEIRO, BRAZIL | February 13, 2023 – Researchers from the Centre for Data and Knowledge Integration for Health and the Federal University of Rio de Janeiro (UFRJ) unveiled ...

Sabin Vaccine Institute [to 18 Feb 2023]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

UNAIDS [to 18 Feb 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.

UNICEF [to 18 Feb 2023]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Remarks
14 February 2023
Hundreds of thousands of children enduring desperate conditions following Türkiye and Syria earthquakes
https://www.unicef.org/press-releases/hundreds-thousands-children-enduring-desperate-conditions-following-t%C3%BCrkiye-and
GENEVA, 14 February 2023 – " As families face the wretched, heartbreaking reality that the focus in Türkiye and Syria is moving to recovery more than rescue, UNICEF fears many thousands of children have been killed. Even without verified numbers, it is tragically clear that numbers will continue grow. "In Türkiye, the total number of children...

Unitaid [to 18 Feb 2023]
LAPaL, the Long-Acting Therapeutics Patents and Licences Database, is now available with enhanced features to track new drug development

An enhanced collaborative tool at hand to support access to innovative long-acting therapeutics

Seattle, 18 February 2023 – During a workshop held prior to the Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Charles Flexner, the Principal Investigator of the Long-Acting/Extended Release Antiretroviral Research Resource Program (LEAP) today announced, on behalf of all partners, a new version of the Long-Acting Therapeutics Patents and Licences Database LAPaL.

Launched in 2021 by the Medicines Patent Pool with support from Unitaid, LAPaL is a free online dynamic resource that provides information on technical features, development status and intellectual property status of selected long-acting therapeutics that could have health impact in low- and middle-income countries...

Vaccine Equity Cooperative [nee Initiative] [to 18 Feb 2023]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 18 Feb 2023]
https://www.vaccineacceptance.org/
Announcements, Blog
2nd Annual Vaccination Acceptance Research Network Conference
VARN2023 Registration
Conference dates: June 13-15, 2023
Conference location: Bangkok, Thailand (venue information to come)

Vaccine Confidence Project [to 18 Feb 2023]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 18 Feb 2023]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 18 Feb 2023]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.
The Wistar Institute  [to 18 Feb 2023]
Media
No new digest content identified.

WFPHA: World Federation of Public Health Associations  [to 18 Feb 2023]
https://www.wfpha.org/
Latest News - Blog
Letter to the People of Türkiye and Syria in the Aftermath of the Earthquake
Feb 16, 2023
We send our heartfelt condolences to the people of the Republic of Türkiye and the Syrian Arab Republic affected by the earthquake..

World Medical Association [WMA]  [to 18 Feb 2023]
Press Releases
No new digest content identified.

World Organisation for Animal Health (OIE)  [to 18 Feb 2023]
https://www.oie.int/en/
Press Releases, Statements
Statements
Statement on avian influenza and mammals
Published on 13 February 2023

:::

ARM [Alliance for Regenerative Medicine]  [to 18 Feb 2023]
Selected Press Releases
No new digest content identified.

BIO  [to 18 Feb 2023]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network  [to 18 Feb 2023]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.
**ICBA – International Council of Biotechnology Associations**  [to 18 Feb 2023]  
https://internationalbiotech.org/news/

News
No new digest content identified.

**IFPMA**  [to 18 Feb 2023]  
http://www.ifpma.org/resources/news-releases/

*Selected Press Releases, Statements, Publications*

*Statement* 15 Feb 2023
**WHO briefing for relevant stakeholders on the Zero Draft WHO CA+**

- On 15 February, IFPMA attended a briefing for relevant stakeholders on the Zero Draft WHO CA+ in Geneva and delivered a statement on industry’s preliminary comments.

*Press release* 13 Feb 2023
**Pharma recommends five priorities for future pandemic preparedness and response**

**International Alliance of Patients’ Organizations – IAPO**  [to 18 Feb 2023]  
https://www.iapo.org.uk/news/topic/6

*Press and media [Selected]*
No new digest announcements identified.

**International Generic and Biosimilar Medicines Association [IGBA]**  
https://www.igbamedicines.org/

*News*
**IGBA’s 25th Annual Conference highlights the true value of the off-patent medicines industry for patients and health systems around the world**

Orlando, 15 February 2023

IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that experts and leaders from the local and global generic and biosimilar medicines industries, Government and regulatory agencies, academia and other stakeholders are meeting from 15 to 16 February in Orlando, Florida to discuss key topics affecting worldwide patient access to affordable quality-assured medicines, such as

- addressing the supply chain resiliency,
- tackling the misuse of pharmaceutical intellectual property rights,
- overcoming reputational challenges,
- mitigating shortages,
- advancing global regulatory convergence, harmonization and resilience,
- strengthening the global supply chain in a context of political and trade frictions, and
- discussing trends and policies that shape the competitive market environment, impacting the sustainability of the off-patent pharmaceutical sector, and hence medium and long-term reliable and affordable access to essential medicines.

**PhRMA**  [to 18 Feb 2023]
http://www.phrma.org/
Press Releases
No new digest announcements identified.

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases - No new digest announcements identified

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - Website not responding at inquiry

Biological E
News - No new digest announcements identified

BioNTech
Press Releases - No new digest announcements identified

Boehringer
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinnagen
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News
Feb 14, 2023
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
--As part of China’s second booster campaign, Clover’s premium, broadly protective protein-based vaccine is now available in Zhejiang province with additional provinces and municipalities to follow in Q1 2023—

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia above.

GSK
Press releases for media
15 February 2023
Landmark New England Journal of Medicine publication reinforces potential of GSK’s respiratory syncytial virus older adult vaccine candidate
First peer-reviewed publication of phase III RSV vaccine data in older adults, including those with comorbidities who are most at risk.

14 February 2023
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023
Other key data to be presented include new HIV prevention findings for long-acting cabotegravir and predictors of response to N6LS

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Merck
News releases - No new digest announcements identified

Moderna
Press Releases
17 February, 2023
Health Canada Authorizes Moderna’s Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)

16 February, 2023
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate

Nanogen
News - No new digest announcements identified

Novartis
News - No new digest announcements identified

Novavax
Press Releases
Feb 13, 2023
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax’ COVID-19 Vaccine

Pfizer
Recent Press Releases - No new digest announcements identified

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases - No new digest announcements identified

SK Biosciences
Press Releases - No new digest announcements identified

Takeda
Newsroom - No new digest announcements identified

Valneva
Press Releases
February 17, 2023
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

February 14, 2023
Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Vector State Research Centre of Viralology and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 14, 2023 Issue 1
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 25, Number 2: E89-165

Child Abuse and Neglect
Child abuse is so common that it has become a subspecialty in pediatrics. Indeed, children are 40 times more likely to be confirmed victims of abuse or neglect than to be diagnosed with cancer. “Upstream” obligations to help prevent abuse and neglect of children accompany clinicians’ “downstream” obligations as mandatory reporters, first responders, secondary illness and injury documentarians, and gatherers of forensic evidence. Since clinicians are also key communicators with children, perpetrators, parents, and colleagues during or following clinical encounters, how well they promote short- and long-term healing among persons who are or were victims of child abuse or neglect is often a function of how well they express trauma-informed care values in practice. This theme issue also considers how clinicians should best promote healing among persons, including themselves, who struggle to manage their own psychological and emotional secondary trauma responses when taking care of children who are abused and neglected.

American Journal of Infection Control
February 2023 Volume 51 Issue 2 p121-240
American Journal of Preventive Medicine
February 2023  Volume 64  Issue 2  p149-304
https://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
February 2023  113(2)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
Volume 108 (2023): Issue 2 (Feb 2023)
https://www.ajtmh.org/view/journals/tpmd/108/2/tpmd.108.issue-2.xml
[Reviewed earlier]

Annals of Internal Medicine
January 2023  Volume 176, Issue 1
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 315  February 2023
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 18 Feb 2023)
[No new digest content identified]

BMJ Global Health
February 2023 - Volume 8 - 2
https://gh.bmj.com/content/8/2
Original research
The impact of economic sanctions on health and health systems in low-income and middle-income countries: a systematic review and narrative synthesis (9 February, 2023)
Matteo Pinna Pintor, Marc Suhrcke, Christoph Hamelmann

Practice
Digital public health leadership in the global fight for health security (15 February, 2023)
Bandar AlKnawy, Zisis Kozlakidis, Sasu Tarkoma, David Bates, Antti Honkela, George Crooks, Kyu Rhee, Mollie McKillop

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 18 Feb 2023)
[No new digest content identified]

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 18 Feb 2023)
Serological response to vaccination in post-acute sequelae of COVID
Individuals with post-acute sequelae of COVID (PASC) may have a persistence in immune activation that differentiates them from individuals who have recovered from COVID without clinical sequelae. To investigate...
Authors: Sandy Joung, Brittany Weber, Min Wu, Yunxian Liu, Amber B. Tang, Matthew Driver, Sarah Sternbach, Timothy Wynter, Amy Hoang, Denisse Barajas, Yu Hung Kao, Briana Khuu, Michelle Bravo, Hibah Masoom, Teresa Tran, Nancy Sun...
Citation: BMC Infectious Diseases 2023 23:97
Content type: Research Published on: 16 February 2023

Results from a systematic programme of evaluating COVID-19 reinfection cases in the early phase of the pandemic, Singapore
The objectives of this study were to describe the coronavirus disease caused by SARS-CoV-2 (COVID-19) reinfection evaluation algorithm used in the early phase of the pandemic in Singapore and analyze the clini...
Authors: Glorijoy Shi En Tan, Christine Qiuhan Gao, Jievanda Shu Ying Ow, Thuan Thong Tan, Say Tat Ooi, Cui Lin, Raymond Tzer Pin Lin, Vernon Jian Ming Lee, Monica Chan, Yee Sin Leo and Shawn Vasoo
Citation: BMC Infectious Diseases 2023 23:93
Content type: Research Published on: 14 February 2023

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 18 Feb 2023)
Key ethical issues encountered during COVID-19 research: a thematic analysis of perspectives from South African research ethics committees
The COVID-19 pandemic presents significant challenges to research ethics committees (RECs) in balancing urgency of review of COVID-19 research with careful consideration of risks and benefits. In the African context, RECs are further challenged by historical mistrust of research and potential impacts on COVID-19 related research participation, as well as the need to facilitate equitable access to effective treatments or vaccines for COVID-19. In South Africa, an absent National Health Research Ethics Council (NHREC) also left RECs without national guidance for a significant duration of the COVID-19 pandemic. We conducted a qualitative descriptive study that explored the perspectives and experiences of RECs regarding the ethical challenges of COVID-19 research in South Africa.

**BMC Medicine**
http://www.biomedcentral.com/bmcmed/content
(Accessed 18 Feb 2023)
[No new digest content identified]

**BMC Pregnancy and Childbirth**
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 18 Feb 2023)
[No new digest content identified]

**BMC Public Health**
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 18 Feb 2023)
**Impact of the COVID-19 pandemic and the dynamic COVID-zero strategy on HIV incidence and mortality in China**
*In response to the coronavirus disease 2019 (COVID-19) pandemic, the Chinese government implemented the dynamic COVID-zero strategy. We hypothesized that pandemic mitigation measures might have reduced the incidence...*
Authors: Lan Wang, Na Zhao, Yuliang Wang, Kaili Sun, Yike Wang, Shufang Huang, Feng Yao, Xiangyu Guo, Yunmei Yang, Chenjin Ma and Shelan Liu
Citation: BMC Public Health 2023 23:361
Content type: Research Published on: 18 February 2023

**The social determinants of national tuberculosis incidence rates in 116 countries: a longitudinal ecological study between 2005–2015**
*Accelerating declines in tuberculosis (TB) incidence is paramount for achieving global goals set for 2030 by the Sustainable Development Goals and the End TB Strategy. The aim of this study was to identify key...*
Authors: Fiona A. Költringer, Kristi Sidney Annerstedt, Delia Boccia, Daniel J. Carter and William E. Rudgard
Citation: BMC Public Health 2023 23:337
Content type: Research Published on: 15 February 2023
Parents’ intention to vaccinate their 5- to 11-year-old children with the COVID-19 vaccine: rates, predictors and the role of incentives

Immediately after Pfizer announced encouraging effectiveness and safety results from their COVID-19 vaccine clinical trials in 5- to 11-year-old children, this study aimed to assess parents’ perceptions and in...

Authors: Liora Shmueli
Citation: BMC Public Health 2023 23:328
Content type: Research Published on: 14 February 2023

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 18 Feb 2023)
[No new digest content identified]

BMJ Evidence-Based Medicine
February 2023 - Volume 28 - 1
https://ebm.bmj.com/content/28/1
[Reviewed earlier]

BMJ Open
January 2023 - Volume 13 - 1
https://bmjopen.bmj.com/content/13/1
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 101(2); 2023 Feb 1
https://www.ncbi.nlm.nih.gov/pmc/issues/427334/
[Reviewed earlier]

Cell
Feb 02, 2023  Volume 186  Issue 3  p461-662
https://www.cell.com/cell/current
[Reviewed earlier]

Child Care, Health and Development
Volume 49, Issue 2  Pages: 211-406  March 2023
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 113, Issue 2  Pages: 197-445  February 2023
Historically, pediatric medicines are developed after adult trials are completed, even when identical drug targets and disease similarities exist across the populations. This has resulted in significant delays in the authorization of medicines for adolescent use, limiting access to beneficial drugs. This study sought to understand how adolescent inclusion in adult trials is positioned in regulatory guidance documents as they set critical expectations for trial design and regulatory decision-making.
Current Opinion in Infectious Diseases
February 2023 - Volume 36 - Issue 1
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
HIV INFECTIONS AND AIDS
Estimating the global impact of coronavirus disease 2019 on people living with HIV
Thornhill, John; Orkin, Chloe; Cevik, Muge

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 4 Pages: 181-299 December 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 33, Issue 1, 2023
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Development Policy Review
Volume 41, Issue 1 January 2023
https://onlinelibrary.wiley.com/toc/14677679/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 6 - December 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
The New Humanitarian Crisis in Ukraine: Coping With the Public Health Impact of Hybrid Warfare, Mass Migration, and Mental Health Trauma
Sonny S. Patel, Timothy B. Erickson
Published online by Cambridge University Press: 23 March 2022, pp. 2231-2232

Disasters
EMBO Reports
Volume 24  Issue 2  6 February 2023
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 29, Number 1—January 2023
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 41  December 2022
https://www.sciencedirect.com/journal/epidemics/vol/41/suppl/C
[Reviewed earlier]

Epidemiology and Infection
Volume 151 - 2023
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 45, Issue 1 Pages: 1-38  January–February 2023
https://onlinelibrary.wiley.com/toc/25782363/current
Ancillary-care obligations - Evaluating public policy interventions
[Reviewed earlier]

Ethics & International Affairs
Winter 2022 (36.4)  December 21, 2022
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 25  December 2022
[Reviewed earlier]
The European Journal of Public Health
Volume 32, Issue 6, December 2022
https://academic.oup.com/eurpub/issue/32/6
[Reviewed earlier]

Expert Review of Vaccines
Vol 22 (1) 2023 Issue In Progress
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 101, Number 6 November/December 2022
https://www.foreignaffairs.com/issues/2022/101/6
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 3
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genetics in Medicines
Volume 25, Issue 1 Pages A1-A10, 1-166 (January 2023)
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/1
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 18 Feb 2023]
[No new digest content identified]

Global Health Action
Volume 16, Issue 1 (2023)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
December 2022 | Volume 10 | Number 6
http://www.ghspjournal.org/content/current
[Reviewed earlier]
Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 18 Feb 2023]
[No new digest content identified]

Global Public Health
Volume 18, Issue 1 (2023)
http://www.tandfonline.com/toc/rgph20/current
[New issue; No digest content identified]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 18 Feb 2023]
[No new digest content identified]

Health and Human Rights
Volume 24, Issue 2, December 2022
Special Section: COVID-19 Vaccine Equity and Human Rights
[Reviewed earlier]

Health Economics, Policy and Law
Volume 18 - Issue 1 - January 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 37, Issue 10, December 2022
https://academic.oup.com/heapol/issue/37/10
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 18 Feb 2023]
[No new digest content identified]

Human Gene Therapy
Volume 34, Issue 3–4 / February 2023
https://www.liebertpub.com/toc/hum/34/3-4
[New issue; No digest content identified]
Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

Immunity
Jan 10, 2023 Volume 56 Issue 1 p1-224
https://www.cell.com/immunity/current
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 18 Feb 2023]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 18 Feb 2023]
[No new digest content identified]

International Health
Volume 15, Issue 1, January 2023
https://academic.oup.com/inthealth/issue/15/1
[Reviewed earlier]

International Human Rights Law Review
Volume 11 (2022): Issue 2 (Dec 2022)
https://brill.com/view/journals/hrlr/11/2/hrlr.11.issue-2.xml
Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol. 10 No. 1 (2023): January 2023
https://www.ijcmph.com/index.php/ijcmph/issue/view/96
[Reviewed earlier]
International Journal of Epidemiology
Volume 51, Issue 6, December 2022
https://academic.oup.com/ije/issue
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 15 Issue 3, 2022
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3
Special Issue: Children, young people and their international human right to healthcare
[Reviewed earlier]

JAMA
February 14, 2023, Vol 329, No. 6, Pages 447-520
https://jamanetwork.com/journals/jama/currentissue
Original Investigation
Household Transmission of Influenza A Viruses in 2021-2022
Melissa A. Rolfes, PhD, MPH; H. Keipp Talbot, MD; Huong Q. McLean, PhD, MPH; et al. free access
This prospective study compares the risk of transmission of influenza virus infection among household contacts of patients with influenza during the 2021-2022 influenza season vs before the COVID-19 pandemic influenza seasons in the US.

JAMA Health Forum
February 2023, Vol 4, No. 2
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

JAMA Pediatrics
February 2023, Vol 177, No. 2, Pages 107-216
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
February 2023 - Volume 21 - Issue 2
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
February 2023 Volume 72 Issue 2 p161-314
Journal of Artificial Intelligence Research
Vol. 76 (2023)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 6, December 2022
https://link.springer.com/journal/10900/volumes-and-issues/47-6
[Reviewed earlier]

Journal of Development Economics
Volume 161 March 2023
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 5, December 2022
http://journals.sagepub.com/toc/jre/current
Ethical Issues using Digital Surveillance Technologies in Research
[Reviewed earlier]

Journal of Epidemiology & Community Health
March 2023 - Volume 77 - 3
https://jech.bmj.com/content/77/3
[New issue; No digest content identified]

Journal of Evidence-Based Medicine
Volume 15, Issue 4 Pages: 315-424 December 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 18, Issue 2, 2022
http://www.tandfonline.com/toc/rige20/current
[Reviewed earlier]
Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 34, Number 1, February 2023
https://muse.jhu.edu/issue/49033
Table of Contents
[New issue; No digest content identified]

Journal of Immigrant and Minority Health
Volume 25, issue 1, February 2023
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 21, 2023 - Issue 1
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 227, Issue 3, 1 February 2023
https://academic.oup.com/jid/issue/227/3
[New issue; No digest content identified]

Journal of International Development
Volume 35, Issue 1 Pages: 1-197 January 2023
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

Journal of Medical Ethics
February 2023 - Volume 49 - 2
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 10, Issue 1 (2023)
https://institutionalrepository.aah.org/jpcrr/
[New issue; No digest content identified]

Journal of Pediatrics
January 2023 Volume 252 p1-226
http://www.jpeds.com/current
[Reviewed earlier]
Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 18 Feb 2023]
[No new digest content identified]

Journal of Public Health Management & Practice
January/February 2023 - Volume 29 - Issue 1
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 43, issue 4, December 2022
https://link.springer.com/journal/41271/volumes-and-issues/43-4
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
February 2023  Volume 20  Issue 199
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 29, Issue 8, December 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 96  Number 24  December 2022
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Feb 18, 2023  Volume 401  Number 10376  p525-616
https://www.thelancet.com/journals/lancet/issue/current
Series
One Health

Advancing One human–animal–environment Health for global health security: what does the evidence say?
Jakob Zinsstag, et al.

Summary
In this Series paper, we review the contributions of One Health approaches (ie, at the human–animal–environment interface) to improve global health security across a range of health hazards and we summarise contemporary evidence of incremental benefits of a One Health approach. We assessed how One Health approaches were reported to the Food and Agricultural Organization of the UN, the World Organisation for Animal Health (WOAH, formerly OIE), and WHO, within the monitoring and assessment frameworks, including WHO International Health Regulations (2005) and WOAH Performance of Veterinary Services. We reviewed One Health theoretical foundations, methods, and case studies. Examples from joint health services and infrastructure, surveillance–response systems, surveillance of antimicrobial resistance, food safety and security, environmental hazards, water and sanitation, and zoonoses control clearly show incremental benefits of One Health approaches. One Health approaches appear to be most effective and sustainable in the prevention, preparedness, and early detection and investigation of evolving risks and hazards; the evidence base for their application is strongest in the control of endemic and neglected tropical diseases. For benefits to be maximised and extended, improved One Health operationalisation is needed by strengthening multisectoral coordination mechanisms at national, regional, and global levels.

One Health

A global analysis of One Health Networks and the proliferation of One Health collaborations
Athman Mwatondo, et al.

Summary
There has been a renewed focus on threats to the human–animal–environment interface as a result of the COVID-19 pandemic, and investments in One Health collaborations are expected to increase. Efforts to monitor the development of One Health Networks (OHNs) are essential to avoid duplication or misalignment of investments. This Series paper shows the global distribution of existing OHNs and assesses their collective characteristics to identify potential deficits in the ways OHNs have formed and to help increase the effectiveness of investments. We searched PubMed, Google, Google Scholar, and relevant conference websites for potential OHNs and identified 184 worldwide for further analysis. We developed four case studies to show important findings from our research and exemplify best practices in One Health operationalisation. Our findings show that, although more OHNs were formed in the past 10 years than in the preceding decade, investment in OHNs has not been equitably distributed; more OHNs are formed and headquartered in Europe than in any other region, and emerging infections and novel pathogens were the priority focus area for most OHNs, with fewer OHNs focusing on other important hazards and pressing threats to health security. We found substantial deficits in the OHNs collaboration model regarding the diversity of stakeholder and sector representation, which we argue impedes effective and equitable OHN formation and contributes to other imbalances in OHN distribution and priorities. These findings are supported by previous evidence that shows the skewed investment in One Health thus far. The increased attention to One Health after the COVID-19 pandemic is an opportunity to focus efforts and resources to areas that need them most. Analyses, such as this Series paper, should be used to establish databases and repositories of OHNs worldwide. Increased attention should then be given to understanding existing resource allocation and distribution patterns, establish more egalitarian networks that encompass the breadth of One Health issues, and serve
communities most affected by emerging, re-emerging, or endemic threats at the human–animal–
environment interface.

**The Lancet Child & Adolescent Health**
Feb 2023 Volume 7 Number 2 p77-144, e2-e4
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

**Lancet Digital Health**
Feb 2023 Volume 5 Number 2 e51-e101
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

**Lancet Global Health**
Feb 2023 Volume 11 Number 2 e170-e300
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

**Lancet Infectious Diseases**
Feb 2023 Volume 23 Number 2 p131-260, e47-e71
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

**Lancet Public Health**
Feb 2023 Volume 8 Number 2 e85-e160
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

**Lancet Respiratory Medicine**
Feb 2023 Volume 11 Number 2 p111-212, e12-e19
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

**Maternal and Child Health Journal**
Volume 27, issue 1, January 2023
[Reviewed earlier]

**Medical Decision Making (MDM)**
Volume 43 Issue 2, February 2023
Generating 'smarter' biotechnology

Generative AI is moving full speed ahead in the biomedical space.

... Overall in 2022, over $1.37 billion was invested into generative AI companies, and as this software gains more traction in the biomedical space, this amount is likely to increase. There have been predictions that generative AI could result in $1 trillion in value for the healthcare industry by 2040. We still need improvements in the training data to avoid bias, and we need to make them more user- and planet-friendly, but the technology has the potential to influence cancer detection, predict disease variants and mitigate climate change. Certainly there are other applications that we haven't even considered — maybe we should ask ChatGPT what it thinks.

Comment 02 Feb 2023

Delivering 3 billion doses of Comirnaty in 2021

Pfizer created a 'light-speed' approach to meet the challenge of vaccinating the world against COVID-19. It involved developing new strategies for all aspects of vaccine development, from sourcing materials and scaling up manufacturing to transportation and dosing.

Nicholas Warne, Margaret Ruesch, Mikael Dolsten
The Singapore National Precision Medicine Strategy

This Perspective article discusses Singapore’s efforts to implement a National Precision Medicine Strategy through the integration of genomic, clinical and lifestyle data of up to one million Singaporean individuals.
Eleanor Wong, Nicolas Bertin, Patrick Tan

Nature Human Behaviour
Volume 7 Issue 1, January 2023
https://www.nature.com/nathumbehav/volumes/7/issues/1
[Reviewed earlier]

Nature Medicine
Volume 29 Issue 1, January 2023
https://www.nature.com/nm/volumes/29/issues/1
[Reviewed earlier]

Nature Reviews Drug Discovery
Volume 22 Issue 2, February 2023
https://www.nature.com/nrd/volumes/22/issues/2
[Reviewed earlier]

Nature Reviews Genetics
Volume 24 Issue 2, February 2023
https://www.nature.com/nrg/volumes/24/issues/2
[Reviewed earlier]

Nature Reviews Immunology
Volume 23 Issue 2, February 2023
https://www.nature.com/nri/volumes/23/issues/2

Host-directed immunotherapy of viral and bacterial infections: past, present and future

In this Perspective, the authors reflect on the historical development of host-directed immunotherapeutic interventions for viral and bacterial infections, and then focus on how historical insights can be applied to current approaches to therapy of SARS-CoV-2 and Mycobacterium tuberculosis infections.
Robert S. Wallis, Anne O’Garra, Andreas Wack

New England Journal of Medicine
February 16, 2023 Vol. 388 No. 7
https://www.nejm.org/toc/nejm/medical-journal
Perspective
Choosing the Right Path toward Polio Eradication
K. Chumakov, C. Brechot, R.C. Gallo, and S. Plotkin

... In the past, the GPEI’s strategic thinking was guided by a scientific advisory committee, but that committee was disbanded years ago, in part because of the perception that science was no longer needed because eradication was just around the corner. This wishful thinking has prevailed for the past 30 years and has proven counterproductive.

The original 1988 World Health Assembly declaration called for eradication of poliomyelitis, emphasizing that “eradication efforts should be pursued in ways which strengthen the development of the Expanded Programme on Immunization as a whole, fostering its contribution, in turn, to the development of the health infrastructure and of primary health care.” We believe the GPEI should revert to the declaration’s original intent of eradicating the disease by creating universal immunity to polio rather than continue pursuing viral eradication that has been unsuccessful. It is important to engage the entire scientific and public health communities in developing a rational and sustainable future polio-immunization strategy. We urge the WHO and all their partners, including Rotary International and the Bill and Melinda Gates Foundation, to initiate an open dialogue with scientists about the strategy for preventing polio.

The Journey to RSV Vaccines — Heralding an Era of Structure-Based Design
B.S. Graham

Original Articles
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
A. Papi and Others

Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults
A.R. Falsey and Others

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
F.M. Muñoz and Others

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 18 Feb 2023]
[No new digest content identified]

Pediatrics
Volume 151, Issue 2 February 2023
https://publications.aap.org/pediatrics/issue/151/2
[Reviewed earlier]

PharmacoEconomics
Volume 41, issue 2, February 2023
[Reviewed earlier]
Living with “long COVID”: A systematic review and meta-synthesis of qualitative evidence
M. Mahbub Hossain, Jyoti Das, Farzana Rahman, Fazilatun Nesa, Puspita Hossain, A. M. Khairul Islam, Samia Tasnim, Farah Faizah, Hoimonty Mazumder, Neetu Purohit, Gilbert Ramirez
Research Article | published 16 Feb 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0281884

Assessing the relationship between operationally defined zero-dose communities and access to selected primary healthcare services for children and pregnant women in emergency settings
Mark P. Suprenant, Elevanie Nyankesha, Ralfh Moreno-Garcia, Valentina Buj, Ahmadu Yakubu, Fouzia Shafique, Muhammad H. Zaman
Research Article | published 16 Feb 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0281764

The impact of the COVID-19 pandemic and the expansion of free vaccination policy on influenza vaccination coverage: An analysis of vaccination behavior in South Korea
Muhan Yeo, Jeongmin Seo, Juwon Lim
Research Article | published 15 Feb 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0281812
Global inequity creates local insufficiency: A qualitative study of COVID-19 vaccine implementation challenges in low-and-middle-income countries
Victoria Haldane, Archchun Ariyarajah, Isha Berry, Miranda Loutet, Fabio Salamanca-Buentello, Ross E. G. Upshur
Research Article | published 13 Feb 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0281358

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 18 Feb 2023]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
February 14, 2023, vol. 120 no. 7
https://www.pnas.org/toc/pnas/120/7
Brief Report February 8, 2023 Coronavirus (COVID-19)
The political polarization of COVID-19 treatments among physicians and laypeople in the United States
In the United States, liberals and conservatives disagree about facts. To what extent does expertise attenuate these disagreements? To study this question, we compare the polarization of beliefs about COVID-19 treatments among laypeople and critical care ...
Joel M. Levin, Leigh A. Bukowski,[...]
Journal M. Kahn
Research Article February 7, 2023
Resolving content moderation dilemmas between free speech and harmful misinformation
In online content moderation, two key values may come into conflict: protecting freedom of expression and preventing harm. Robust rules based in part on how citizens think about these moral dilemmas are necessary to deal with this conflict in a principled ...
Anastasia Kozyreva, Stefan M. Herzog,[...]
Jason Reifler
PNAS Nexus
Volume 2, Issue 2, February 2023
IN PROGRESS
https://academic.oup.com/pnasnexus/issue
[New issue; No digest content identified]

Prehospital & Disaster Medicine
Volume 38 - Issue 1 - February 2023
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 166 January 2023
Proceedings of the Royal Society B
08 February 2023  Volume 290  Issue 1992
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 214  Pages 1-180 (January 2023)
[Reviewed earlier]

Public Health Ethics
Volume 15, Issue 3, November 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 138 Issue 1, January/February 2023
https://journals.sagepub.com/toc/phrg/138/1
[Reviewed earlier]

Qualitative Health Research
Volume 33 Issue 3, February 2023
https://journals.sagepub.com/toc/qhra/current
[New issue; No digest content identified]

Research Ethics
Volume 19 Issue 1, January 2023
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 18 Feb 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
Risk Analysis
Volume 43, Issue 1  Pages: 1-201  January 2023
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Global Systemic Risk and Resilience for Novel Coronavirus with Evolving Perspectives
EDITORIAL
Global systemic risk and resilience for novel coronavirus with evolving perspectives
Desheng Wu, Jade Mitchell, James H. Lambert
Pages: 5-7
First Published: 15 February 2023

Risk Management and Healthcare Policy
[Accessed 18 Feb 2023]
[No new digest content identified]

Science
Volume 379| Issue 6633| 17 Feb 2023
https://www.science.org/toc/science/current
Policy Forum
Leveraging IP for AI governance
BY C. D. Schmit, et al.
16 Feb 2023: 646-648
Copyleft AI with Trusted Enforcement (CAITE) can support an adaptable soft law approach for ethics in AI

Science and Engineering Ethics
Volume 29, issue 1, February 2023
https://link.springer.com/journal/11948/volumes-and-issues/29-1
[New issue; No digest content identified]

Science Translational Medicine
Volume 15| Issue 683| 15 Feb 2023
https://www.science.org/toc/stm/current
[New issue; No digest content identified]

Social Science & Medicine
Volume 318  February 2023
Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 18 Feb 2023]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 43, issue 5-6, December 2022
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 51  January–February 2023
[Reviewed earlier]

Tropical Medicine & International Health
Volume 28, Issue 2  Pages: i-iv, 71-156  February 2023
https://onlinelibrary.wiley.com/toc/13653156/current
[New issue; No digest content identified]

Vaccine
Volume 41, Issue 5  Pages 999-1176 (27 January 2023)
https://www.sciencedirect.com/journal/vaccine/vol/41/issue/5
Selected Content
Short communication  Full text access
COVID-19 booster vaccination in rural community pharmacies
Abigail Gamble, Tessa J. Hastings, Salisa C. Westrick, Megan Smith, ... Delesha M. Carpenter
Pages 999-1002

Review article  Open access
A systematic review of communication interventions for countering vaccine misinformation
Hannah S. Whitehead, Clare E. French, Deborah M. Caldwell, Louise Letley, Sandra Mounier-Jack
Pages 1018-1034

Research article  Abstract only
Comparing the effect of parental education via both lecture and film upon vaccination uptake for children under one year of age: A cluster randomized clinical trial
Azam Songol, Leila Amiri-Farahani, Shima Haghani, Sally Pezaro, Soghra Omrani Saravi
Pages 1067-1073
COVID-19 vaccination refusal trends in Kenya over 2021
Ryan T. Rego, Brooke Kenney, Anthony K. Ngugi, Leon Espira, ... Akbar K. Waljee
Pages 1161-1168

School staff as vaccine advocates: Perspectives on vaccine mandates and the student registration process
Mark C. Navin, Aaron M. Scherer, Ethan Bradley, Katie Attwell
Pages 1169-1175

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 18 Feb 2023]

Parental Decision Making Regarding COVID-19 Vaccines for Children under Age 5: Does Decision Self-Efficacy Play a Role?
by Jennifer D. Allen

COVID-19 Vaccine Uptake and Associated Factors in Sub-Saharan Africa: Evidence from a Community-Based Survey in Tanzania
by Sia E. Msuya

Value in Health
February 2023 Volume 26 Issue 2 p151-316
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

Pre-Print Servers
Gates Open Research
https://gatesopenresearch.org/browse/articles
Selected Research

Research Article

metrics

Revised

Circulation of respiratory viruses during the COVID-19 pandemic in The Gambia
[version 2; peer review: 2 approved]
Peer Reviewers Ivy A. Asante; Antonia Ho
Funders
Bill and Melinda Gates Foundation
Global Challenge Research Fund award from The University of Sheffield
UK Research and Innovation grant
LATEST VERSION PUBLISHED 16 Feb 2023

Research Article

metrics AWAITING PEER REVIEW

The economic costs of malaria in pregnancy: evidence from four sub-Saharan countries
[version 1; peer review: awaiting peer review]
Laia Cirera, Charfeddin Sacoor, Martin Meremikwu, Louise Ranaivo, Manu F. Manun'Ebbo, Dachi Arikpo, Oswaledo Matavele, Victor Rafaralahy, Didier Ndome, Clara Pons Duran, Maximo Ramirez, Francesco Ramponi, Raquel González, Christina Maly, Elaine Roman, Elisa Sicuri, Franco Pagnoni, Clara Menéndez
Peer Reviewers Invited
Funders
Generalitat de Catalunya - CERCA Program
‘Centro de Excelencia Severo Ochoa 2019–2023’ Program Jhpiego
UNITAID
PUBLISHED 15 Feb 2023

medRxiv

https://www.medrxiv.org/content/about-medrxiv
[Filter: All articles]

Selected Research

The importance of vaccinated individuals to population-level evolution of pathogens
Maria A. Gutierrez, Julia R. Gog
medRxiv 2022.11.29.22282822; doi: https://doi.org/10.1101/2022.11.29.22282822 Revision

Changes of sociobehavioural characteristics and HIV in 29 Sub-Saharan African countries, 2000–2018
Jeffrey Post, Wingston Ng'ambi, Olivia Keiser, Aziza Merzouki
medRxiv 2023.02.16.23286024; doi: https://doi.org/10.1101/2023.02.16.23286024

HIV epidemics and associated sociobehavioural characteristics vary widely across Sub-Saharan African (SSA) countries. In this study, we investigated how national changes on sociobehavioural characteristics may be associated with trajectories in HIV epidemics. Methods: We analyzed aggregated
data from 80 DHS surveys of 29 SSA countries between 2000 and 2018. We described each national survey by 46 pre-selected demographic, socio-economic, behavioural and HIV-related variables...

The Changing Global Epidemiology of Re-emerging Human Monkeypox Virus Infection: A Systematic Review
Sunder Sham, FNU Sapna, FNU Anjali, Sanjay Kumar, Vivek Podder, Soumya Jaladi, Ahmed Bendari, Reham Al-Refai, Manal Mohammad Baloch, Mohammed Abdelwahed, FNU Kiran, Hansini Laharwani

COVID-19 Vaccine Acceptance in Nigeria: A Rapid Systematic Review and Meta-Analysis
Victory Chizaram Nnaemeka, Nnenna Audrey Okafor, Oluwatosin Qawiyy Orababa, Ruth Anikwe, Reuben Ogba Onwe, Nneka Patricia Uzochukwu, Thomas Sambo Tsiterimam, Nkiru Nenye Nwokoye, Anthony Chibuogwu Ike
medRxiv 2023.02.16.23286008; doi: https://doi.org/10.1101/2023.02.16.23286008

Water, Sanitation and Cholera in sub-Saharan Africa
Mustafa Sikder, Aniruddha Deshpande, Sonia T. Hegde, Espoir Bwenge Malembaka, Karin Gallandat, Robert C. Reiner, Justin Lessler, Elizabeth C. Lee, Andrew S. Azman
medRxiv 2023.02.15.23285991; doi: https://doi.org/10.1101/2023.02.15.23285991

Abstract
Improvements in water and sanitation should reduce cholera risk. But it is unclear which water and sanitation access are associated with cholera risk. We estimated the association between eight water and sanitation measures and annual cholera incidence access across sub-Saharan Africa (2010-2016) for data aggregated at the country and district-level. We fit random forest regression and classification models to understand how well these measures combined might be able to predict cholera incidence rates and identify high cholera incidence areas. Across spatial scales, piped or “other improved” water access was inversely associated with cholera incidence. Access to piped water, piped sanitation, and piped or “other improved” sanitation were associated with decreased district-level cholera incidence. The classification model had moderate skill in identifying high cholera incidence areas (cross-validated-AUC 0.81 95%CI 0.78–0.83) with high negative predictive values (92.5–100.0%) indicating the utility of water and sanitation measures for screening out areas that are unlikely to be cholera hotspots. While comprehensive cholera risk assessments must incorporate other data sources (e.g., historical incidence), our results suggest that water and sanitation measures could alone be useful in narrowing the geographic focus for detailed risk assessments.

The role of wastewater-based epidemiology for SARS-CoV-2 in developing countries: cumulative evidence from South Africa supports sentinel site surveillance to guide public health decision-making
medRxiv 2023.02.13.23285226; doi: https://doi.org/10.1101/2023.02.13.23285226

Quantifying the rate and magnitude of the Omicron outbreak in China after sudden exit from ‘zero-COVID’ restrictions
Abstract

In late 2022, China transitioned from a strict ‘zero-COVID’ policy to rapidly abandoning nearly all interventions and data reporting. This raised great concern about the presumably-rapid but undisclosed spread of the SARS-CoV-2 Omicron variant in a very large population of very low pre-existing immunity. A quantitative understanding of the epidemic dynamics of COVID-19 during this period is urgently needed. Here, by modeling a combination of case count and survey data, we show that Omicron spread extremely fast, at a rate of 0.42/day (95% CrI: [0.35, 0.51]/day) after the full exit from zero-COVID policies on Dec. 7, 2022. Consequently, we estimate that the vast majority of the population (97%, 95% CrI [95%, 99%]) was infected during December, with the nation-wide epidemic peaking on Dec. 23. Overall, our results highlight the extremely high transmissibility of the variant and the importance of proper design of intervention exit strategies to avoid large infection waves.

Summaries, Analysis and Simulations of Recent COVID-19 Epidemic in Mainland China During December 31 2021-December 6 2022

Lequan Min
medRxiv 2023.02.07.23285380; doi: https://doi.org/10.1101/2023.02.07.23285380 Revision

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%20CLife%20Sciences
[Accessed 06 Jan 2023]
[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]
No new digest content identified.

Wellcome Open Research
https://wellcomeopenresearch.org/browse/articles
[Accessed 06 Jan 2023]
Selected Research
No new digest content identified.

Think Tanks

Brookings [to 18 Feb 2023]
http://www.brookings.edu/
Latest Research [Selected] Technology & Innovation
All Research [Selected] CGD NOTES
No new digest content identified.

Center for Global Development [to 18 Feb 2023]
https://www.cgdev.org/
Independent Thinking: Humanitarian disaster in Syria and Turkey

Episode 15 of our weekly podcast examines the far-reaching consequences of the earthquakes which struck Turkey and Syria on the region’s fragile geopolitics.
16 February 2023  26 min

Expert comment

Syrian rescue efforts slowed by bureaucracy and regime

Help for Syrians following the devastating earthquakes is being hampered by the Assad regime’s control over aid flows and a slow-moving United Nations.
14 February 2023
No new digest content identified.

**Rand** [to 18 Feb 2023]
https://www.rand.org/pubs.html
Published Research [Selected]
Journal Article

**Optimal Non-Pharmaceutical Pandemic Response Strategies Depend Critically on Time Horizons and Costs**
This paper performs a large-scale optimization exercise to find optimal non-pharmaceutical pandemic response strategies.
Feb 14, 2023
Sarah A. Nowak, Pedro Nascimento de Lima, Raffaele Vardavas

**Urban Institute** [to 18 Feb 2023]
https://www.urban.org/publications

**New Research Publications - Selected**

**World Economic Forum** [to 18 Feb 2023]
https://agenda.weforum.org/news/
Media

*No new digest content identified.*

---

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::
CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.